RxDoctor Payments DataLook up a doctor →

Hailey Armstrong

Family · Albertville, ALNPI 1326463175

Payments from drug & device makers

$12,316in general payments, 2019–2025

Across 782 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$878
  • Lilly USA, LLC$822
  • AstraZeneca$658
  • Pfizer$630
  • plus $6K from 42 others

What the payments were for

  • Consulting fees$1131%
  • Food & beverage$12,10898%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,316 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$106,527
Medicare patients
297
Services billed
1,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide122$150,331
FarxigaDapagliflozin Propanediol82$71,115
OzempicSemaglutide41$42,258
Janumet XrSitagliptin Phos/Metformin Hcl42$35,543
JardianceEmpagliflozin44$30,787
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,662
JanuviaSitagliptin Phosphate27$22,508
EliquisApixaban35$22,386
LinzessLinaclotide21$21,944
Tresiba Flextouch U-200Insulin Degludec30$18,015
MyrbetriqMirabegron24$16,191
RybelsusSemaglutide15$13,728
GemtesaVibegron14$10,029
EntrestoSacubitril/Valsartan11$9,859
Lagevrio (Eua)Molnupiravir14$9,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$822$150,331122 claims
AstraZenecaFarxiga$658$71,11582 claims
MerckJanumet Xr, Januvia, Lagevrio (Eua)$378$67,34383 claims
Novo NordiskOzempic, Rybelsus$1,397$55,98656 claims
Boehringer IngelheimJardiance$425$30,78744 claims
GSKTrelegy Ellipta$878$30,66239 claims
AbbVieLinzess, Synthroid$1,906$23,42332 claims
PfizerEliquis$630$22,38635 claims
Astellas Pharma US IncMyrbetriq$110$16,19124 claims
Sumitomo Pharma America, Inc.Gemtesa$487$10,02914 claims
NovartisEntresto$82$9,85911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Albertville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →